Drug Approval | October 26, 2021
Glenmark launches novel fixed-dose combination for diabetes
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
Barbara Engelhardt moves her computational and statistics lab to Gladstone
Packaged junk food which is a major component of unhealthy diets is responsible for more deaths worldwide than any other risk factor
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
Subscribe To Our Newsletter & Stay Updated
